BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...has completed Phase Ia testing to treat solid tumors. Forbius itself was spun out of YM Biosciences Inc....
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...idelalisib (CAL-101) Ph II Cancer 2011 $375M + up to $225M ms Mkt; $92M (1%) YM BioSciences Inc....
BioCentury | Aug 31, 2018
Company News

Sierra Oncology acquires momelotinib from Gilead

...provide details. Gilead gained rights to momelotinib in 2012 through its $510 million acquisition of YM Biosciences Inc....
BioCentury | Nov 16, 2016
Clinical News

Mixed Phase III results for Gilead's momelotinib in myelofibrosis

...and JAK-2 inhibitor from Incyte Corp. (NASDAQ:INCY). Gilead gained momelotinib via its 2012 acquisition of YM BioSciences Inc....
BioCentury | Feb 12, 2016
Clinical News

Incyte discontinues Jakafi trials in solid tumors

...and gemcitabine for previously untreated metastatic pancreatic cancer. Gilead acquired the compound when it bought YM BioSciences...
BioCentury | Jan 5, 2015
Finance

Back for more

...of cancer company Ceptaris Therapeutics Inc. , antibiotics play Rempex Pharmaceuticals Inc. and cancer company YM BioSciences Inc....
...up front plus up to $334 million in milestones. Gilead Sciences Inc. (NASDAQ:GILD) took out YM BioSciences...
BioCentury | Sep 8, 2014
Company News

ProNAi management update

...Mich. Business: Cancer Hired: Nick Glover as president and CEO, formerly president and CEO of YM BioSciences Inc....
BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...glioma. InnoMab Pte. Ltd., a JV between CIMAB and InnoKeys, purchased nimotuzumab in 2012 from YM BioSciences Inc....
BioCentury | Apr 7, 2014
Company News

Pulmokine, NIH cardiovascular news

...exclusive license from Cytopia Ltd. to develop PDGFR inhibitors for PAH under a 2007 deal. YM BioSciences Inc....
BioCentury | Aug 19, 2013
Company News

Tekmira management update

...SVP and CMO, a newly created position, formerly VP of regulatory affairs and CMO of YM BioSciences Inc....
Items per page:
1 - 10 of 229
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...has completed Phase Ia testing to treat solid tumors. Forbius itself was spun out of YM Biosciences Inc....
BioCentury | Dec 15, 2018
Product Development

O’Day’s expansive task at Gilead

...idelalisib (CAL-101) Ph II Cancer 2011 $375M + up to $225M ms Mkt; $92M (1%) YM BioSciences Inc....
BioCentury | Aug 31, 2018
Company News

Sierra Oncology acquires momelotinib from Gilead

...provide details. Gilead gained rights to momelotinib in 2012 through its $510 million acquisition of YM Biosciences Inc....
BioCentury | Nov 16, 2016
Clinical News

Mixed Phase III results for Gilead's momelotinib in myelofibrosis

...and JAK-2 inhibitor from Incyte Corp. (NASDAQ:INCY). Gilead gained momelotinib via its 2012 acquisition of YM BioSciences Inc....
BioCentury | Feb 12, 2016
Clinical News

Incyte discontinues Jakafi trials in solid tumors

...and gemcitabine for previously untreated metastatic pancreatic cancer. Gilead acquired the compound when it bought YM BioSciences...
BioCentury | Jan 5, 2015
Finance

Back for more

...of cancer company Ceptaris Therapeutics Inc. , antibiotics play Rempex Pharmaceuticals Inc. and cancer company YM BioSciences Inc....
...up front plus up to $334 million in milestones. Gilead Sciences Inc. (NASDAQ:GILD) took out YM BioSciences...
BioCentury | Sep 8, 2014
Company News

ProNAi management update

...Mich. Business: Cancer Hired: Nick Glover as president and CEO, formerly president and CEO of YM BioSciences Inc....
BioCentury | May 12, 2014
Clinical News

Nimotuzumab: Phase III discontinued

...glioma. InnoMab Pte. Ltd., a JV between CIMAB and InnoKeys, purchased nimotuzumab in 2012 from YM BioSciences Inc....
BioCentury | Apr 7, 2014
Company News

Pulmokine, NIH cardiovascular news

...exclusive license from Cytopia Ltd. to develop PDGFR inhibitors for PAH under a 2007 deal. YM BioSciences Inc....
BioCentury | Aug 19, 2013
Company News

Tekmira management update

...SVP and CMO, a newly created position, formerly VP of regulatory affairs and CMO of YM BioSciences Inc....
Items per page:
1 - 10 of 229